Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2015

## Total Synthesis of (-)-Cryptocaryol A

Luiz C. Dias,\* Paula K. Kuroishi, and Emílio C. de Lucca Jr.

Instituto de Química, Universidade Estadual de Campinas, 13083-970, C.P. 6154,

Campinas, SP, Brazil

\* ldias@iqm.unicamp.br

## **Table of Contents**

<b>Figure S1.</b> <sup>1</sup> H NMR spectrum of <b>8</b> (250 MHz; $C_6D_6$ ).	S5
Figure S2. <sup>13</sup> C NMR spectrum of 8 (62.5 MHz; $C_6D_6$ ).	S6
Figure S3. <sup>13</sup> C NMR spectrum (DEPT 135) of 8 (62.5 MHz; $C_6D_6$ ).	S6
Figure S4. IR and HRMS spectra of 8.	S7
<b>Figure S5.</b> <sup>1</sup> H NMR spectrum of <b>11</b> (600 MHz; $C_6D_6$ ).	S8
Figure S6. <sup>13</sup> C NMR spectrum of <b>11</b> (125 MHz; $C_6D_6$ ).	S9
Figure S7. <sup>13</sup> C NMR spectrum (DEPT 135) of <b>11</b> (125 MHz; $C_6D_6$ ).	S9
Figure S8. IR and HRMS spectra of 11.	S10
Figure S9. <sup>1</sup> H NMR spectrum of <b>12</b> (500 MHz; CDCl <sub>3</sub> ).	S11
Figure S10. <sup>13</sup> C NMR spectrum of <b>12</b> (125 MHz; CDCl <sub>3</sub> ).	S12
Figure S11. <sup>13</sup> C NMR spectrum (DEPT 135) of 12 (125 MHz; CDCl <sub>3</sub> ).	S12
Figure S12. IR and HRMS spectra of 12.	S13
Figure S13. <sup>1</sup> H NMR spectrum of 13 (400 MHz; CDCI <sub>3</sub> ).	S14
Figure S14. <sup>13</sup> C NMR spectrum of 13 (100 MHz; CDCl <sub>3</sub> ).	S15
Figure S15. <sup>13</sup> C NMR spectrum (DEPT 135) of <b>13</b> (100 MHz; CDCl <sub>3</sub> ).	S15
Figure S16. IR and HRMS spectra of 13.	S16

<b>Figure S17.</b> <sup>1</sup> H NMR spectrum of <b>14</b> (500 MHz; $CDCI_3$ ).	S17
Figure S18. <sup>13</sup> C NMR spectrum of 14 (125 MHz; CDCl <sub>3</sub> ).	S18
Figure S19. <sup>13</sup> C NMR spectrum (DEPT 135) of 14 (125 MHz; CDCl <sub>3</sub> ).	S18
Figure S20. COSY contour map for 14.	S19
Figure S21. HSQC contour map for 14.	S20
Figure S22. HMBC contour map for 14.	S21
Figure S23. IR and HRMS spectra of 14.	S22
Figure S24. <sup>1</sup> H NMR spectrum of 6 (250 MHz; CDCl <sub>3</sub> ).	S23
Figure S25. <sup>13</sup> C NMR spectrum of 6 (62.5 MHz; CDCl <sub>3</sub> ).	S24
Figure S26. <sup>13</sup> C NMR spectrum (DEPT 135) of 6 (62.5 MHz; $CDCI_3$ ).	S24
Figure S27. IR and HRMS spectra of 6.	S25
<b>Figure S28.</b> <sup>1</sup> H NMR spectrum of <b>15</b> (500 MHz; $C_6D_6$ ).	S26
Figure S29. <sup>13</sup> C NMR spectrum of <b>15</b> (125 MHz; $C_6D_6$ ).	S27
Figure S30. <sup>13</sup> C NMR spectrum (DEPT 135) of <b>15</b> (125 MHz; $C_6D_6$ ).	S27
Figure S31. IR and HRMS spectra of 15.	S28
Figure S32. <sup>1</sup> H NMR spectrum of 16 (500 MHz; CDCI <sub>3</sub> ).	S29
Figure S33. <sup>13</sup> C NMR spectrum of 16 (125 MHz; CDCl <sub>3</sub> ).	S30
Figure S34. <sup>13</sup> C NMR spectrum (DEPT 135) of 16 (125 MHz; CDCl <sub>3</sub> ).	S30
Figure S35. IR and HRMS spectra of 16.	S31
Figure S36. <sup>1</sup> H NMR spectrum of <b>17</b> (500 MHz; CDCl <sub>3</sub> ).	S32
Figure S37. <sup>13</sup> C NMR spectrum of <b>17</b> (125 MHz; CDCl <sub>3</sub> ).	S33
Figure S38. <sup>13</sup> C NMR spectrum (DEPT 135) of <b>17</b> (125 MHz; CDCl <sub>3</sub> ).	S33
Figure S39. IR and HRMS spectra of 17.	S34
Figure S40. <sup>1</sup> H NMR spectrum of 18 (500 MHz; MeOD).	S35
Figure S41. <sup>13</sup> C NMR spectrum of 18 (125 MHz; MeOD).	S36

Figure S42. <sup>13</sup> C NMR spectrum (DEPT 135) of 18 (125 MHz; MeOD).	S36
Figure S43. COSY contour map for 18.	S37
Figure S44. HSQC contour map for 18.	S38
Figure S45. HMBC contour map for 18.	S39
Figure S46. IR and HRMS spectra of 18.	S40
Figure S47. <sup>1</sup> H NMR spectrum of <b>19</b> (500 MHz; CDCl <sub>3</sub> ).	S41
Figure S48. <sup>13</sup> C NMR spectrum of <b>19</b> (125 MHz; CDCl <sub>3</sub> ).	S42
Figure S49. <sup>13</sup> C NMR spectrum (DEPT 135) of <b>19</b> (125 MHz; CDCl <sub>3</sub> ).	S42
Figure S50. IR and HRMS spectra of 19.	S43
Figure S51. <sup>1</sup> H NMR spectrum of 20 (600 MHz; CDCl <sub>3</sub> ).	S44
Figure S52. <sup>13</sup> C NMR spectrum of 20 (150 MHz; CDCl <sub>3</sub> ).	S45
Figure S53. <sup>13</sup> C NMR spectrum (DEPT 135) of 20 (150 MHz; CDCl <sub>3</sub> ).	S45
Figure S54. IR and HRMS spectra of 20.	S46
Figure S55. <sup>1</sup> H NMR spectrum of 2 (250 MHz; CDCl <sub>3</sub> ).	S47
Figure S56. <sup>13</sup> C NMR spectrum of 2 (62.5 MHz; CDCl <sub>3</sub> ).	S48
Figure S57. <sup>13</sup> C NMR spectrum (DEPT 135) of <b>2</b> (62.5 MHz; $CDCI_3$ ).	S48
Figure S58. IR and HRMS spectra of 2.	S49
Figure S59. <sup>1</sup> H NMR spectrum of 1 (500 MHz; MeOD).	S50
Figure S60. <sup>13</sup> C NMR spectrum of 1 (125 MHz; MeOD).	S51
Figure S61. <sup>13</sup> C NMR spectrum (DEPT 135) of 1 (125 MHz; MeOD).	S51
Figure S62. COSY contour map for 1.	S52
Figure S63. HSQC contour map for 1.	S53
Figure S64. HMBC contour map for 1.	S54
Figure S65. IR and HRMS spectra of 1.	S55
Table 1. <sup>1</sup> H and <sup>13</sup> C NMR chemical shifts for cryptocaryol A.	S56

Attempts to optimize de aldol reaction	S57
Scheme S1.	S57
Figure S66.	S57
Scheme S2.	S58
Scheme S3.	S59
Scheme S4.	S59
Scheme S5.	S60
Scheme S6.	S60
Scheme S7.	S61
Scheme S8.	S61
Scheme S9.	S62









Figure S4. IR spectrum of 8.

![](_page_7_Figure_0.jpeg)

S8

![](_page_8_Figure_0.jpeg)

S9

![](_page_9_Figure_0.jpeg)

Figure S8. IR and HRMS spectra of 11.

![](_page_10_Figure_0.jpeg)

![](_page_11_Figure_0.jpeg)

![](_page_11_Figure_1.jpeg)

![](_page_12_Figure_0.jpeg)

Figure S12. IR and HRMS spectra of 12.

Acquisition Time (sec)	1.9923	Date	30 Apr 2013 16:0	00:54			
File Name	F:\Mestrado\Esp	ectros RMN\400\abr30pkkł	H1 (PKK17)_00100	)1r	Frequency (MHz)	400.18	
Nucleus	1H	Number of Transients	16	Original Points Count	16384	Points Count	32768
Pulse Sequence	zg30	Solvent	CHLOROFORM	-D		Sweep Width (Hz)	8223.68
Temperature (degree C	) 25.260						

 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 1.1
 <th1.1</th>
 <th1.1</th>
 <th1.1</th>

![](_page_13_Figure_2.jpeg)

![](_page_14_Figure_0.jpeg)

![](_page_15_Figure_0.jpeg)

![](_page_15_Figure_1.jpeg)

![](_page_16_Figure_0.jpeg)

![](_page_17_Figure_0.jpeg)

Figure S19. <sup>13</sup>C NMR spectrum (DEPT 135) of **14** (125 MHz; CDCl<sub>3</sub>).

![](_page_18_Figure_0.jpeg)

Paula - PKK 15 - CDC13 - Avance 500 MHz - abr15pkkH1- COSY

Figure S20. COSY contour map for 14.

![](_page_19_Figure_0.jpeg)

Paula - PKK 15 - CDCl3 - Avance 500 MHz - abr15pkkH1- HSQC

Figure S21. HSQC contour map for 14.

![](_page_20_Figure_0.jpeg)

Paula - PKK 15 - CDCl3 - Avance 500 MHz - abr15pkkH1- HMBC

Figure S22. HMBC contour map for 14.

![](_page_21_Figure_0.jpeg)

Figure S23. IR and HRMS spectra of 14.

![](_page_22_Figure_0.jpeg)

![](_page_23_Figure_0.jpeg)

![](_page_24_Figure_0.jpeg)

Figure S27. IR and HRMS spectra of 6.

![](_page_25_Figure_0.jpeg)

• •

![](_page_26_Figure_0.jpeg)

Figure S29. <sup>13</sup>C NMR spectrum of **15** (125 MHz; C<sub>6</sub>D<sub>6</sub>).

![](_page_26_Figure_2.jpeg)

![](_page_27_Figure_0.jpeg)

Figure S31. IR and HRMS spectra of 15.

![](_page_28_Figure_0.jpeg)

![](_page_29_Figure_0.jpeg)

Figure S34. <sup>13</sup>C NMR spectrum (DEPT 135) of **16**(125 MHz; CDCl<sub>3</sub>).

![](_page_30_Figure_0.jpeg)

![](_page_30_Figure_1.jpeg)

![](_page_31_Figure_0.jpeg)

![](_page_31_Figure_1.jpeg)

![](_page_32_Figure_0.jpeg)

![](_page_33_Figure_0.jpeg)

Figure S39. IR and HRMS spectra of 17.

![](_page_34_Figure_0.jpeg)

![](_page_35_Figure_0.jpeg)

![](_page_35_Figure_1.jpeg)

![](_page_36_Figure_0.jpeg)

Paula - PKK102 - MeOD - Avance 400 MHz - mar28pkkH1 - COSY

Figure S43. COSY contour map for 18.

![](_page_37_Figure_0.jpeg)

Paula - PKK102 - MeOD - Avance 400 MHz - mar28pkkH1 HSQC

Figure S44. HSQC contour map for 18.

![](_page_38_Figure_0.jpeg)

Paula - PKK102 - MeOD - Avance 400 MHz - mar28pkkH1 HMBC

Figure S45. HMBC contour map for 18.

![](_page_39_Figure_0.jpeg)

Figure S46. IR and HRMS spectra of 18.

![](_page_40_Figure_0.jpeg)

![](_page_41_Figure_0.jpeg)

![](_page_42_Figure_0.jpeg)

Figure S50. IR and HRMS spectra of 19.

![](_page_43_Figure_0.jpeg)

![](_page_43_Figure_1.jpeg)

![](_page_44_Figure_0.jpeg)

**Figure S53.** <sup>13</sup>C NMR spectrum (DEPT 135) of **20** (150 MHz; CDCl<sub>3</sub>).

![](_page_45_Figure_0.jpeg)

Figure S54. IR and HRMS spectra of 20.

![](_page_46_Figure_0.jpeg)

![](_page_47_Figure_0.jpeg)

![](_page_48_Figure_0.jpeg)

Figure S58. IR and HRMS spectra of 2.

![](_page_49_Figure_0.jpeg)

![](_page_50_Figure_0.jpeg)

<sup>168</sup> 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0 **Figure S60.** <sup>13</sup>C NMR spectrum of **1** (125 MHz; MeOD).

![](_page_50_Figure_2.jpeg)

Figure S61. <sup>13</sup>C NMR spectrum (DEPT 135) of 1 (125 MHz; MeOD).

![](_page_51_Figure_0.jpeg)

Figure S62. COSY contour map for 1.

![](_page_52_Figure_0.jpeg)

Figure S63. HSQC contour map for 1.

![](_page_53_Figure_0.jpeg)

Paula - PKK96 - MeOD / Av600 MHz - out23pkkH1 - HMBC

Figure S64. HMBC contour map for 1.

![](_page_54_Figure_0.jpeg)

Figure S65. IR and HRMS spectra of 1.

Position	Natural Product			0	Dias Synthetic Product			O'Doherty Synthetic Product		
	δ <sup>13</sup> C	$\delta^{1}H$	multiplicity ( <i>J</i> in Hz)	δ <sup>13</sup> C <sup>c</sup>	δ <sup>1</sup> H <sup>a</sup>	multiplicity ( <i>J</i> in Hz)	δ <sup>13</sup> C	δ <sup>1</sup> Η	multiplicity ( <i>J</i> in Hz)	
2	167.0			167.0			167.0			
3	121.4	5.97	dd (9.8, 1.9)	121.4	5.97	dd (9.6, 1.9)	121.4	5.97	dd (9.6, 2.5)	
4	148.6	7.04	ddd (9.8, 6.0, 2.3)	148.5	7.05	ddd (9.6, 5.9, 2.4)	148.6	7.04	ddd (9.6, 6.0, 2.8)	
5a	31.0	2.45	m	30.9	2.45	m	31.0	2.45	ddd (19.2, 5.2, 5.2)	
5b		2.36	ddt (18.5, 11.8, 2.6)		2.36	ddt (18.5, 11.7, 2.5)		2.36	dddd (19.2, 11.6, 2.8, 2.8)	
6	76.6	4.71	m	76.6	4.71	m	76.6	4.67-4.74	m	
7a	43.9	1.94	ddd (14.5, 9.7, 2.3)	43.9	1.94	ddd (14.4, 9.9, 2.5)	43.9	1.94	ddd (14.8, 9.6, 2.8)	
7b		1.67	m		1.66	m		1.55-1.71	m	
8	66.6	4.08	m	66.6	4.08	m	66.6	4.09	(dddd, 8.8, 6.4, 6.4, 2.4)	
9	46.0	1.68	m	46.0	1.63	m	46.0	1.55-1.71	m	
10	69.9	3.97	m	69.9	4.00	m	69.9	3.96-4.04	m	
11a	45.3	1.64	m	45.2	1.67	m	45.3	1.55-1.71	m	
11b					1.60	m				
12	70.2	4.00	m	70.1	4.00	m	70.2	3.96-4.04	m	
13	45.9	1.59	m	45.9	1.63	m	45.9	1.55-1.71	m	
14	68.3	4.02	m	68.2	4.02	m	68.2	3.96-4.04	m	
15	45.8	1.50	m	45.7	1.51	m	45.8	1.49-1.52	m	
16	69.1	3.79	m	69.1	3.80	m	69.1	3.77-3.82	m	
17	39.3	1.43	m	39.2	1.44	m	39.3	1.40-1.46	m	
18a	26.8	1.32	m	26.8	1.43	m	26.8	1.25-1.32	m	
18b					1,33	m				
19-28	30.5-31.0	1.27-1.29	br s	30.5-30.9	1.24-1.36	br s	30.5-31.0	1.25-1.32	br s	
29	33.2	1.29	m	33.1	1.28	m	33.1	1.25-1.32	m	
30	23.8	1.27	m	23.7	1.31	m	23.8	1.25-1.32	m	
31	14.5	0.89	t (6.9)	14.4	0.89	t (7.0)	14.5	0.89	t (6.8)	

**Table S1.** <sup>1</sup>H and <sup>13</sup>C NMR chemical shifts for natural and synthetic cryptocaryol A.

<sup>a</sup> Assignment based on COSY, HSQC, and HMBC experiments.

## Attempts to optimize de aldol reaction

To improve the yields in the last three steps of the (–)-cryptocaryol A synthesis, we first investigated the influence of the solvents in the aldol coupling. In the original procedure,  $Et_2O$  was used for enolization of methyl ketone *Z*-2, and a solution of hexadecanal in  $CH_2Cl_2$  was added to the pre-formed enolate. We envisioned that using  $CH_2Cl_2$  for both the enolization and aldehyde addition may improve the yield; however, only traces of the desired product were observed (Scheme S1).

![](_page_56_Figure_2.jpeg)

Analysis of the byproducts from the aldol reaction in  $CH_2Cl_2$  by <sup>1</sup>H NMR revealed a new signal at 6.77 ppm (doublet of triplets, J = 16.1, 7.1 Hz) corresponding to an *E* alkene. Unfortunately, the new peak corresponds to the isomerization product of compound *Z*-2 under the reaction conditions (Figure S66).

![](_page_56_Figure_4.jpeg)

We attributed the isomerization of methyl ketone Z-2 to the complexation of the Lewis acid, (*c*-Hex)<sub>2</sub>BCl, to the ester carbonyl. Thus, we began by investigating milder

enolization conditions to reduce the degradation of the starting material. Under the standard enolization conditions,  $(c-\text{Hex})_2$ BCl is added to a solution of the methyl ketone at 0 °C, followed by addition of Et<sub>3</sub>N. After 30 minutes, the reaction mixture is cooled to -78 °C, and a solution of the aldehyde is added. Therefore, we envisioned that reducing the enolization time or adding the Lewis acid to a mixture of the ketone and aldehyde in the aldol coupling may improve the yield. To investigate the effect of time and the order of addition of reagents, we used model methyl ketone **22**.

First, we performed the enolization of methyl ketone **22** in the presence of aldehyde **3**. However, only traces of the desired product were obtained. Next,  $(c-\text{Hex})_2\text{BCI}$ was added to a solution of Et<sub>3</sub>N and methyl ketone, and the enolate was allowed to form over 5 min before addition of the aldehyde. Under these conditions, the aldol adduct **23** was obtained in 16% yield (Scheme S2). However, the low yield in this reaction is inconsistent with the reaction progress observed on TLC. Therefore, we believe that the product degraded during purification on column chromatography.

![](_page_57_Figure_2.jpeg)

## Scheme S2.

To avoid potential degradation of aldol adduct **23**, the crude product was used in the subsequent step without purification by column chromatography. Therefore, the aldol reaction was accomplished according to Scheme S2b. After quenching the excess Lewis acid with MeOH, the volatiles were removed under reduced pressure, and the residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with H<sub>2</sub>O to remove excess Et<sub>3</sub>N•HCl formed during the reaction. The organic layer was concentrated and the crude product was submitted to a 1,3-*anti* reduction using the Evans method.<sup>1</sup> However, the crude aldol adduct **23** was insoluble in the solvent mixture (MeCN and AcOH) used for this reaction. Only a small amount of diol **24** was obtained and 10% of compound **23** was recovered (Scheme S3).

<sup>&</sup>lt;sup>1</sup> a) Evans, D. A.; Chapman, K. T. *Tetrahedron Lett.* **1986**, *27*, 5939. b) Evans, D. A.; Chapman, K. T.; Carreira, E. M. *J. Am. Chem. Soc.* **1988**, *110*, 3560.

![](_page_58_Figure_0.jpeg)

![](_page_58_Figure_1.jpeg)

Based on the poor solubility and yield for the 1,3-*anti* reduction, we decided to use an alternative method described by Dieckmann and Menche to effect the aldol reaction and subsequent reduction.<sup>2</sup> This method uses Ipc<sub>2</sub>BCI as a Lewis acid in the initial aldol coupling between a methyl ketone and an aldehyde followed by a subsequent asymmetric reduction of the ketone carbonyl upon warming. The aldol reaction and tandem reduction affords products with 1,5-*anti* and 1,3-*syn* stereochemistry.

Application of the Dieckmann and Menche methodology to ketone **22** afforded the desired aldol product; however, no reduction of the ketone carbonyl was observed after 24 hours at room temperature by TLC (Scheme S4).

![](_page_58_Figure_4.jpeg)

Scheme S4.

As an alternative, the aldol reaction was performed using (+)-lpc<sub>2</sub>BCl, and the corresponding product was reduced using the Evans method with THF as solvent. However, the solubility of compound **23** in THF was low and only 16% of diol **24** was obtained (Scheme S5).

<sup>&</sup>lt;sup>2</sup> Dieckmann, M.; Menche, D. *Org.Lett.* **2013**, *15*, 228.

![](_page_59_Figure_0.jpeg)

Scheme S5.

Since optimization of both the aldol coupling between **22** and **3** and the reduction of **23** were difficult, we decided to protect the hydroxyl of **23** as the TES ether with TESOTf to improve its solubility for a stereoselective carbonyl reduction. Therefore, the aldol reaction involving methyl ketone **22** and aldehyde **3** was quenched by addition of TESOTf at –78 °C, and gradually warmed to room temperature (Scheme S6a). However, the TLC of aldol reaction after the addition of TESOTf remained the same and the desired silyl ether was not isolated.

We envisioned that the silvl protection failed because the Lewis acid was still coordinated to the secondary alcohol. Therefore, the aldol reaction was accomplished again, and after the reaction was complete the excess Lewis acid was quenched with MeOH and the reaction medium was washed with H<sub>2</sub>O. The crude product was then treated with TESOTf and 2,6-lutidine, but only a complex mixture of byproducts was observed (Scheme S6b).<sup>3</sup>

![](_page_59_Figure_4.jpeg)

Scheme S6.

Finally, we decided to investigate the influence of eluents used during purification of the aldol adduct by column chromatography. Model substrate **26** was submitted twice to the aldol reaction conditions shown in Scheme S7. Purification of **27** was first performed by loading the crude product on the column with CH<sub>2</sub>Cl<sub>2</sub>, followed by using a mixture of

<sup>&</sup>lt;sup>3</sup> Greene, T. W.; Wuts, P. G. M. *Protective Groups in Organic Synthesis*, 4<sup>a</sup> ed.; John Wiley & Sons; Nova York, 2007.

hexane and ethyl acetate as eluent. With these conditions, only traces of the desired product were isolated.

For the second purification, the crude product was loaded on the column with  $CH_2CI_2$  and this solvent was also used as eluent. In this case, the aldol adduct **27** was obtained in 44% yield, which is a superior yield to those observed for reactions involving aldehyde **3**.

![](_page_60_Figure_2.jpeg)

![](_page_60_Figure_3.jpeg)

The reduction step was then optimized by substituting MeCN, used in the Evans methodology, for  $CH_2Cl_2$ , which can solubilize both the starting material and reducing agent. Reaction of aldol adduct **27** with  $Me_4NHB(OAc)_3$  in  $CH_2Cl_2$  and AcOH afforded diol **28** in 99% yield, which demonstrates that  $CH_2Cl_2$  is the ideal solvent for substrate **27** (Scheme S8). Furthermore, aldol adduct **27** could be reduced to diol **28** under the optimized conditions, albeit in poor yield.

![](_page_60_Figure_5.jpeg)

With the optimized conditions for the model substrate in hand, we next applied them to the actual substrate. Since the solvent mixture did not influence the yields in the aldol reaction,  $Et_2O$  was used for enolization of methyl ketone **2** (Scheme S8). The aldol adduct was then purified with a mixture of  $CH_2Cl_2$ :AcOEt (9:1) as eluent. Subsequent reduction of the aldol adduct under the Evans conditions using  $CH_2Cl_2$  afforded compound **21**. The crude product was partially purified by column chromatography and then treated with CSA in MeOH to give (–)-cryptocaryol A in 1.1% yield over 3 steps (Scheme S9).

![](_page_61_Figure_0.jpeg)

Scheme S9.